# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!


Hemophagocytic Lymphohistiocytosis (HLH)

Hemophagocytic lymphohistiocytosis
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 21-26 of 26 results.
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
Status: Recruiting
Last Changed: May 21, 2019
First Received: May 01, 2018
Disease(s): Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Acquired Neutropenia in Newborn, Acquired Anemia Hemolytic, Acquired Thrombocytopenia, Hemophagocytic Lymphohistiocytoses, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Common Variable Immunodeficiency, X-linked Lymphoproliferative Disease, Severe Combined Immunodeficiency, Hurler Syndrome, Mannosidosis, Adrenoleukodystrophy
Intervention(s): Thiotepa--single daily dose, Thiotepa--escalated dose
Locations: UF Health Shands Children's Hospital, Gainesville, Florida, United States
Early Detection of Epstein-Barr Virus Related Disease.
Status: Recruiting
Last Changed: Jun 05, 2018
First Received: Jun 05, 2018
Disease(s): Post-transplant Lymphoproliferative Disorder, Mononucleosis, Epstein-Barr Virus Infections, Epstein-Barr Virus Related Malignancy, Epstein-Barr Viraemia, Epstein-Barr Virus-Related Hodgkin Lymphoma, Epstein-Barr Virus-Related Non-Hodgkin Lymphoma, Hemophagocytic Lymphohistiocytoses, Hemophagocytosis
Locations: Aarhus University Hospital, Aarhus, Central Region Of Denmark, Denmark
Immune Disorder HSCT Protocol
Status: Recruiting
Last Changed: Mar 26, 2019
First Received: Apr 01, 2013
Disease(s): Immune Deficiency Disorders, Severe Combined Immunodeficiency, Chronic Granulomatous Disease, X-linked Agammaglobulinemia, Wiskott-Aldrich Syndrome, Hyper-IgM, DiGeorge Syndrome, Chediak-Higashi Syndrome, Common Variable Immune Deficiency, Immune Dysregulatory Disorders, Hemophagocytic Lymphohistiocytosis, IPEX, Autoimmune Lymphoproliferative Syndrome, X-linked Lymphoproliferative Syndrome
Intervention(s): Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
Locations: Washington University, Saint Louis, Missouri, United States
Methodist Heathcare, San Antonio, Texas, United States
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Status: Recruiting
Last Changed: Jan 15, 2019
First Received: Jul 27, 2012
Disease(s): SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome, Bare Lymphocyte Syndrome, Common Variable Immunodeficiency, Chronic Granulomatous Disease, CD40 Ligand Deficiency, Hyper IgM Syndrome, X-linked Lymphoproliferative Disease, Hemophagocytic Lymphohistiocytosis, Griscelli Syndrome, Chediak-Higashi Syndrome, Langerhan's Cell Histiocytosis
Intervention(s): Alemtuzumab 0.3 mg, Cyclophosphamide, Busulfan, Stem Cell Transplantation, Fludarabine phosphate 40 mg, Melphalan, Alemtuzumab 0.2 mg, Busulfan, Fludarabine phosphate 30 mg, MESNA
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Status: Recruiting
Last Changed: Apr 05, 2019
First Received: Oct 14, 2013
Disease(s): Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions
Intervention(s): Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Locations: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders
Status: Recruiting
Last Changed: Aug 19, 2019
First Received: Jun 12, 2009
Disease(s): Hematopoietic Cell Transplantation Recipient, Non-Malignant
Intervention(s): Allogeneic Bone Marrow Transplantation, Anti-Thymocyte Globulin, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation, Treosulfan, Umbilical Cord Blood Transplantation
Locations: Children's Hospital Colorado, Aurora, Colorado, United States
Oregon Health and Science University, Portland, Oregon, United States
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Seattle Children's Hospital, Seattle, Washington, United States
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
... and 2 other locations.